GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoveren Scientific Inc (OTCPK:IVRN) » Definitions » Cyclically Adjusted Price-to-FCF

Innoveren Scientific (Innoveren Scientific) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Innoveren Scientific Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Innoveren Scientific Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Innoveren Scientific's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoveren Scientific Cyclically Adjusted Price-to-FCF Chart

Innoveren Scientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Innoveren Scientific Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innoveren Scientific's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Innoveren Scientific's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoveren Scientific's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoveren Scientific's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Innoveren Scientific's Cyclically Adjusted Price-to-FCF falls into.



Innoveren Scientific Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Innoveren Scientific's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Innoveren Scientific's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.478/129.8595*129.8595
=-0.478

Current CPI (Sep. 2023) = 129.8595.

Innoveren Scientific Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 98.326 0.000
201403 -46.556 99.695 -60.643
201406 -79.222 100.560 -102.305
201409 -64.444 100.428 -83.330
201412 -119.000 99.070 -155.984
201503 -138.111 99.621 -180.032
201506 -214.500 100.684 -276.657
201509 -130.091 100.392 -168.277
201512 -90.000 99.792 -117.117
201603 -88.167 100.470 -113.957
201606 -101.462 101.688 -129.571
201609 -117.000 101.861 -149.160
201612 -106.929 101.863 -136.318
201703 -91.125 102.862 -115.042
201706 -67.000 103.349 -84.186
201709 -60.571 104.136 -75.533
201712 -75.909 104.011 -94.774
201803 -45.765 105.290 -56.445
201806 -6.824 106.317 -8.335
201809 -23.130 106.507 -28.202
201812 -9.000 105.998 -11.026
201903 -45.151 107.251 -54.669
201906 -25.958 108.070 -31.192
201909 -15.646 108.329 -18.756
201912 -45.237 108.420 -54.182
202003 -18.910 108.902 -22.549
202006 -23.728 108.767 -28.329
202009 -1.696 109.815 -2.006
202012 -14.262 109.897 -16.853
202103 -10.227 111.754 -11.884
202106 -10.435 114.631 -11.821
202109 -8.782 115.734 -9.854
202112 -5.043 117.630 -5.567
202203 -5.231 121.301 -5.600
202206 -2.923 125.017 -3.036
202209 -1.039 125.227 -1.077
202212 -0.230 125.222 -0.239
202303 -0.585 127.348 -0.597
202306 -0.129 128.729 -0.130
202309 -0.478 129.860 -0.478

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Innoveren Scientific  (OTCPK:IVRN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Innoveren Scientific Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Innoveren Scientific's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoveren Scientific (Innoveren Scientific) Business Description

Traded in Other Exchanges
N/A
Address
2202 N West Shore Boulevard, Suite 200, Tampa, FL, USA, 33607
Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.
Executives
Fwhc Holdings, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Hoa Capital Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Farrior J Rex Iii 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Fwhc Bridge Friends, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Raymond Monteleone director 201 E KENNEDY BLVD, STE 700, TAMPA FL 33602
Jeremy Daniel officer: Chief Financial Officer 201 E KENNEDY AVE, STE 700, TAMPA FL 33602
Robert Smith Greif officer: President and C.E.O. 19 MAY STREET, NEEDHAM MA 02492
Cfrs Investments, Llc 10 percent owner 2903 W VILLA ROSA PARK, TAMPA FL 33611
Frederick J Lynch 10 percent owner C/O MASONITE INTERNATIONAL CORPORATION, 201 NORTH FRANKLIN ST., SUITE 300, TAMPA FL 33602
Fwhc Bridge, Llc 10 percent owner 334 EAST LAKE ROAD, SUITE 176, PALM HARBOT FL 34685
Todd R Wagner 10 percent owner 3385 OLD KEYSTONE ROAD, TARPON SPRINGS FL 34688
Michael Yurkowsky director 2380 OLD MILTON PARKWAY, ALPHARETTA GA 30009
William E Horne director, officer: Chief Executive Officer 201 EAST KENNEDY BLVD, SUITE 700, TAMPA FL 33602
Jon Mogford director 714 PLUM HOLLOW DRIVE, COLLEGE STATION TX 77845
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615